Clinical Commissioning Policy: Everolimus for prevention of organ rejection following heart transplantation

Reference: NHS England: 16016/P
### NHS England INFORMATION READER BOX

<table>
<thead>
<tr>
<th>Directorate</th>
<th>Operations and Information</th>
<th>Specialised Commissioning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Operations and Information</td>
<td>Trans. &amp; Corp. Ops.</td>
<td>Commissioning Strategy</td>
</tr>
<tr>
<td>Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nursing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Publications Gateway Reference: 05527s

<table>
<thead>
<tr>
<th>Document Purpose</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Name</td>
<td>Clinical Commissioning Policy 16016/P</td>
</tr>
<tr>
<td>Author</td>
<td>Specialised Commissioning Team</td>
</tr>
<tr>
<td>Publication Date</td>
<td>13 July 2016</td>
</tr>
<tr>
<td>Target Audience</td>
<td>CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs</td>
</tr>
</tbody>
</table>

### Additional Circulation List

<table>
<thead>
<tr>
<th>Description</th>
<th>Not Routinely Commissioned - NHS England will not routinely commission this specialised treatment in accordance with the criteria described in this policy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross Reference</td>
<td>This document is part of a suite of policies with Gateway Reference 05527s.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Superseded Docs (if applicable)</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action Required</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Timing / Deadlines (if applicable)</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Details for further information</td>
<td><a href="mailto:england.specialisedcommissioning@nhs.net">england.specialisedcommissioning@nhs.net</a></td>
</tr>
</tbody>
</table>

### Document Status

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.
Clinical Commissioning Policy: Everolimus for prevention of organ rejection following heart transplantation

First published: July 2016

Prepared by NHS England Specialised Services Clinical Reference Group for Cardiac Surgery

Published by NHS England, in electronic format only.
## Contents

1. Introduction .................................................................................................................. 7
2. Definitions ..................................................................................................................... 7
3. Aims and Objectives .................................................................................................... 8
4. Epidemiology and Needs Assessment .......................................................................... 8
5. Evidence Base ............................................................................................................... 9
6. Documents which have informed this Policy ............................................................... 14
7. Date of Review ............................................................................................................. 14
8. References .................................................................................................................... 15
Policy Statement
NHS England will not routinely commission everolimus for the prevention of organ rejection following heart transplantation in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources. This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement
Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

• Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
• Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary
About heart transplants
Heart transplants can be done for patients in the final stages of heart disease – when no other treatments will work. After transplant, the main goal is to make the heart last as long as possible.

About current treatments
After the transplant, patients need medicines to stop the immune system ‘attacking’ the heart. If this happens the heart can be ‘rejected’.

• These medicines are called ‘anti-rejection’ medicines (or ‘immuno-suppressants’).
• These medicines make you more likely to get infections.

**About the new treatment**

Everolimus is a new anti-rejection medicine for use after a heart transplant. Anti-bodies are an important part of the body's defence system. Everolimus works by stopping the anti-bodies growing – this stops the new heart being rejected.

Different anti-rejection medicines can be used together after transplant. Each have different side effects. Using different anti-rejection medicines together helps to reduce these side effects as much as possible. Having different combinations available helps to find the best ones to use for each patient.

**What we have decided**

NHS England has looked at the proposal to use everolimus as an anti-rejection medicine after heart transplant. We have decided that there is not enough evidence to support this proposal to make this treatment available.
1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission everolimus for prevention of organ rejection following heart transplant.

Allogeneic cardiac transplantation is the transfer of the heart organ from a donor to the host patient. Following the procedure, patients will need immunosuppressants to suppress their immune system and prevent it from attacking and rejecting the heart. These immunosuppressants put the patients at risk of infection and adverse drug effects.

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that exerts an immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T-cells. Everolimus causes immunosuppression via different pathways to other treatments, and has been proposed as an alternative immunosuppressant treatment to prevent organ rejection and kidney dysfunction in patients at immunological risk following an allogeneic cardiac transplant.

2 Definitions

Allogeneic cardiac transplantation is the transfer of the heart organ from a donor to the host patient. Cardiac transplantation has emerged as a viable therapeutic strategy for selected patients with end-stage heart disease, offering extended survival and improved quality of life. Following the procedure, patients will need immunosuppressants to suppress their immune system and prevent it from attacking and rejecting the heart. These immunosuppressants put the patients at risk of infection and adverse drug effects.

Everolimus, a proliferation signal inhibitor, exerts an immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T cells. Everolimus inhibits an intracellular signalling pathway which is triggered upon binding of these T-cell growth factors to their respective receptors, and which normally leads to cell proliferation. The blockage of this signal by everolimus leads to an arrest of the cells at the G1 (first) stage of the cell cycle, preventing allograft rejection.
The effect of everolimus is not restricted to T-cells. It inhibits in general, growth factor-stimulated proliferation of haematopoietic as well as non-haematopoietic cells, such as those of vascular smooth muscle cells. Growth factor-stimulated vascular smooth muscle cell proliferation, triggered by injury to endothelial cells and leading to neointima formation, plays a key role in the pathogenesis of chronic rejection.

3 Aims and Objectives

This policy proposition aims to define NHS England’s commissioning position on everolimus as part of the treatment pathway for immune suppression in adult and paediatric patients post allogenic cardiac transplant.

The objective is to ensure evidence based commissioning in the use of everolimus for the prevention of organ rejection following allogenic cardiac transplant.

4 Epidemiology and Needs Assessment

In 2014/15, there were 181 adult and 37 paediatric heart transplants performed across England (NHS Blood and Transplant, 2015).

Severe renal failure (CKF grade 4 or 5), defined as estimated Glomerular Filtration Rate (eGFR) <30ml/min, affects approximately 4.65% and 9% of patients at three years and five years post heart transplant (NHS Blood and Transplant, 2015). Based on 2013/14 data, approximately 10 patients would suffer severe renal failure at three years post-transplant, and 20 patients at five years post-transplant. There is anecdotal evidence that there is a large number of unidentified patients with significant renal impairment as a result of calcineurin inhibitors (CNIs), who have not reached the stage of dialysis, but whose whole management is very difficult. Chronic renal failure is associated with heightened risk of cardiovascular disorder and other concomitant conditions. Post-transplant patients with chronic renal failure are also at heightened risk of death.
Cardiac allograft vasculopathy (CAV) occurs in >40% of heart transplant patients within 5 years of surgery. Patients with CAV have significantly reduced survival time compared to patients without CAV.

NHS England has considered whether patients with these indications would be suitable for treatment with everolimus.

5 Evidence Base

NHS England has concluded that there is not sufficient evidence to support a proposal for the routine commissioning of everolimus for prevention of organ rejection following heart transplant.

Following a heart transplant, CNIs such as cyclosporine or tacrolimus, are administered in order to reduce the risk of graft loss or acute rejection. CNI exposure is considered to play a key role in renal damage that can cause long term fatal renal failure, although renal failure is not the most common cause of death following heart transplant. Mortality in the first year post-heart transplant is primarily caused by graft failure and infection. Mortality from malignancy and CAV predominates in subsequent years. To improve survival rates and reduce side effects, antiproliferation agents, such as azathioprine and mycophenolate mofetil (MMF), can be used in combination with CNIs. CNIs form the backbone of immunosuppression but are part of a standard triple therapy regimen together with an antimetabolite (MMF or azathioprine) and steroids.

The proliferation signal inhibitors sirolimus or everolimus can be used an alternative to antiproliferation agents i.e. in combination with CNI or as an alternative to CNIs in combination with an antiproliferative agent (e.g. renal sparing strategy). Hence the clinical efficacy and specific advantages of everolimus can be measured in terms of the efficacy in reducing organ rejection or death, impact on renal function, rates of adverse effects (in particular cytomegalovirus (CMV) infections), in addition to the treatment and prevention of CAV.
A literature review was aimed at identifying the current evidence for everolimus post cardiac transplant, specifically to answer the following questions:

1. Is everolimus, in combination with other drugs, clinically effective in preventing organ rejection and adverse effects post cardiac transplant?
2. Does everolimus, in combination with other drugs, offer specific advantages in terms of organ rejection and adverse effects?
3. Is everolimus a cost-effective treatment option for preventing organ rejection and adverse effects post cardiac transplant?

The review found:

- There is level 1 evidence that everolimus, and a reduced cyclosporine dose, is not inferior to MMF and superior to azathioprine in preventing organ rejection. However, everolimus alone is inferior to treatments with cyclosporine.

- There is level 1 evidence that everolimus helps to prevent CAV, but there is no evidence that it is effective against established CAV.

- There is level 1 evidence that everolimus is associated with a reduced CMV infection rate, compared with azathioprine and MMF.

- The evidence that everolimus and a reduced CNI dose results in an improved renal function is conflicted and is likely to be sensitive to the precise details of the CNI dose.

- There is level 1 evidence that everolimus treatment strategies are associated with a reduced risk of leukopenia, but an increased risk of pneumonia and pericardial effusion, when compared with MMF treatments. Overall, during treatment with everolimus a higher number of serious non-fatal adverse events are recorded.

1a. Clinical effectiveness of everolimus in preventing organ rejection post cardiac transplant

The principle outcome for measuring the clinical effectiveness in preventing organ rejection is the rate of biopsy proven acute rejection (BPAR), graded according to international society of heart and lung transplants grading (ISHLT) systems. It is also possible to look at rates of graft loss, death or a composite endpoint (defined as BPAR≥3A, graft loss or death).
• There is level 1 evidence, from 1 large RCT (n=553) with 24 month follow up, that 1.5 mg/day of everolimus with a reduced cyclosporine dose has a statistically similar acute rejection rate to 3 g/day of MMF with a standard cyclosporine dose (24% vs 27%) (Eisen et al., 2013).

• There is level 1 evidence, from 1 large RCT (n=634) with 24 months follow up, that a treatment of everolimus (1.5mg/day) has a lower rate of acute rejections (BPAR≥3A) than a treatment of Azathioprine (34.9% vs 48.1%, p=0.005), with both treatments using a standard cyclosporine dose. The acute rejection rate improved further with 3.0mg/day of everolimus (22.7%). However, subsequent trials with 3.0mg/day of everolimus were halted by the data monitoring committee due to a perceived high mortality rate. The rates of graft loss and death were statistically similar (Vigano et al., 2007).

• A smaller RCT (n=115) found that a treatment schedule including everolimus and MMF, in which the use of CNIs was withdrawn after 7-11 weeks, led to an increase in the acute rejection rate, compared with the use of MMF and cyclosporine (43% vs 15%, p<0.01), (Arora et al., 2015). This result was in agreement with a level 2+ cohort study that found the acute rejection rate for everolimus with a reduced cyclosporine dose was lower than everolimus with no cyclosporine (Gonzalez-Vilchez et al., 2014).

1b. Clinical effectiveness of everolimus in preventing and treating CAV post cardiac transplant

While the rate of CAV is sometimes recorded, it is more productive to measure the impact of treatment schedules on CAV by using an intravascular ultrasound to measure the change, from baseline value, in the coronary maximal intimal thickness (ΔMIT). An incidence of CAV is often defined as ΔMIT ≥ 0.5mm. Other metrics, such as the change in atheroma volume and intimal area, typically mirror the ΔMIT results.

The same two large RCTs and one small RCT all found respectively that 1.5 mg/day everolimus resulted in:

• A ΔMIT=0.07mm compared with azathioprine, ΔMIT=0.15mm, p=0.014, after 24 months (Vigano et al., 2007).
• A ΔMIT=0.03mm compared with MMF, ΔMIT=0.07mm, p<0.001, after 12 months (Eisen et al., 2013).
• A ΔMIT=0.03mm compared with MMF, ΔMIT=0.08mm, p=0.02, after 12 months (Arora et al., 2015).

This resulted in rates of CAV for everolimus of between (12%-33%) vs. (27% - 58%) for azathioprine and MMF treatments.

However, this was based on using everolimus from the first month post-heart transplant, to prevent CAV. A different RCT (n=111) examined the impact of everolimus on patients, an average of 5.8 years post-heart transplant, who had established CAV (mean baseline MIT = 0.56mm). Both the everolimus and MMF arm found no impact on the CAV, ΔMIT=0.0±0.04mm and ΔMIT=0.04±0.04mm respectively (Arora et al., 2011). Likewise, a retrospective cohort study (n=143) found that everolimus and MMF had no impact on MIT between 1 year post-heart transplant and 5 year post-heart transplant (Masetti et al., 2013).

1c. Clinical effectiveness of everolimus in preventing CMV infection post cardiac transplant

There is level 1 evidence that everolimus is associated with a lower incidence of CMV infection. There is good agreement from four RCTs (Eisen et al., 2013 n=553 plus three combined in a meta-analysis in Kobashigawa et al., 2013, n=1009) and one cohort study (Durante-Mangoni et al., 2015, n=378). It is found that the CMV infection rate, when the treatment strategy is using everolimus is between 3-9%. Whereas when azathioprine or MMF is used, this rises to between 19-33%.

2a. Advantages of everolimus, in combination with other drugs, in terms of nephrotoxicity

Renal function can be assessed using creatine clearance or measured/estimated glomerular filtration rates (m/eGFR), all based on creatine concentrations. Although, it was argued in (Stypmann et al., 2015) that deterioration in renal function can occur prior to an increase in serum creatine level. Hence they argue for using Neutrophil gelatinase-associated lipocalin (NGAL) levels.
• During a RCT (n=553) eGFR was found to indicate that 1.5mg/day of everolimus with a reduced cyclosporine dose was inferior to MMF and a standard dose of cyclosporine (a mean change from baseline of eGFR of -0.67 mL/min/1.73 m^2 vs 1.6 mL/min/1.73 m^2). However, closer examination revealed that this difference occurred in the first 3 months post-heart transplant, when both treatments had similar cyclosporine doses (Eisen et al., 2013).
• A RCT (n=115) which used everolimus and no cyclosporine after week 11 compared with MMF and cyclosporine, found that the everolimus arm had a significantly higher mGFR (79.8 mL/min/1.73 m^2 vs 61.5 mL/min/1.73 m^2, p<0.001) after 12 months. Although the same trial reported a higher rate of acute rejections for the everolimus arm (Andreassen et al., 2014).
• Two further RCTs and a Cohort study (n=176, n=70 and n=121) compared everolimus with a reduced cyclosporine dose and MMF with a standard cyclosporine dose. After 12 months no difference in the creatine clearance levels was found in the two RCTs. Although, the everolimus arm had lower levels, but the sample size stopped this from being statistically significant (Lehmkuhl et al., 2009; Bara et al., 2013). The cohort study found plasma and urine NGAL levels significantly lower in the everolimus cohort (p<0.001), favouring the everolimus treatment strategy (Stypmann et al., 2015).

2b. Advantages of everolimus, in combination with other drugs, in terms of adverse effects

In addition to CMV infection there were a large number of additional adverse effects reported during these trials. The majority had similar rates between the respective treatment strategies, but it is worth commenting on the differences. In particular:
• Eisen et al. (2013) and Lehmkuhl et al. (2009) both reported that everolimus treatment strategies had a lower rate of Leukopenia than MMF (13-16% vs 26-30%, p=0.011).
• Eisen et al. (2013) reported that everolimus was associated with higher rates of pericardial effusion than MMF (44% vs 29%, p<0.001).
• Overall patients treated with everolimus had more nonfatal serious adverse events than those treated with MMF (74.2% vs 61.2%) (Eisen et al., 2013).
• Vigano et al. (2007) reported that treatment with everolimus resulted in higher rate of pneumonia than azathioprine (13.9% vs 2.8% p<0.001).

3. Cost effectiveness of everolimus in preventing organ rejection and adverse effects post cardiac transplant

Two studies were found that looked at the cost effectiveness of everolimus treatments. The first compared the total cost of everolimus and azathioprine, with both treatments aiming for standard doses of cyclosporine. The study found that everolimus was marginally more expensive ($72,065 vs $70,815, or £47,910 vs £47,079). This difference was primarily due to increased hospitalisation costs and secondarily due to increased concomitant medication costs, although there were savings made on the cyclosporine costs (Radeva et al., 2005). The second study was based on the German health care model and looked at the incremental cost of everolimus and MMF verses azathioprine divided by the reduction in efficacy failure (the incremental cost effectiveness ratio ICER). The study favoured everolimus over MMF with an ICER of €24,457 vs €29,912 (£17,593 vs £21,516), although the study does not appear to include hospitalisation costs (Annemans et al., 2007).

6 Documents which have informed this Policy

Not applicable.

7 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.
References


Arora, Satish; Ueland, Thor; Wennerblom, Bertil; Sigurdadottir, Vilborg; Eiskjaer, Hans; Bøtker, Hans E.; Ekmehag, Bjorn; Jansson, Kjell; Mortensen, Svend-Aage; Saunamaki, Kari; Simonsen, Svein; Gude, Einar; Bendz, Bjørn; Solbu, Dag; Aukrust, Pål; Gullestad, Lars. Effect of everolimus introduction on cardiac allograft vasculopathy—results of a randomized, multicenter trial. Transplantation. 2011.


Durante-Mangoni, Emanuele; Andini, Roberto; Pinto, Daniela; Iossa, Domenico; Molaro, Rosa; Agrusta, Federica; Casillo, Roberta; Grimaldi, Maria; Utilli, Riccardo.


Lehmkuhl, Hans B.; Arizon, José; Viganò, Mario; Almenar, Luis; Gerosa, Gino; Maccherini, Massimo; Varnous, Shaida; Musumeci, Francesco; Hexham, J. Mark; Mange, Kevin C.; Livi, Ugolino; 2411 Study Investigators. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009.


Stypmann, Jörg; Fobker, Manfred; Rosing, Katharina; Engelen, Markus; Gunia, Stefan; Dell’Aquila, Angelo Maria; Nofer, Jerzy-Roch. Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy. J Cardiol. 2015.

Viganò, Mario; Tuzcu, Murat; Benza, Raymond; Boissonnat, Pascale; Haverich, Axel; Hill, James; Laufer, Guenther; Love, Robert; Parameshwar, Jayan; Pulpoń, Luis Alonso; Renlund, Dale; Abeywickrama, Kamal; Cretin, Nathalie; Starling, Randall C.; Eisen, Howard J.; RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J. Heart Lung Transplant. 2007.